Clinical Trial Update: Epigenetic Modulation in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) [Phase 2]

View source ↗

Summary

Phase 2 trial of an epigenetic modulation approach in relapsed/refractory Diffuse Large B-Cell Lymphoma was terminated; results were posted in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Epigenetic modulation therapy (unspecified agent)

Snippet

Sponsor: Anne Beaven, MD | Conditions: Diffuse Large B-cell Lymphoma | Phase 2 | Status: TERMINATED | Results posted: 2016-06-07